Form 4: Assertio Holdings COO Granted Equity Awards

Assertio Holdings' President and COO, Paul Schwichtenberg, received 24,820 restricted stock units and 27,888 stock options.

Summary

• Paul Schwichtenberg, President and COO of Assertio Holdings, Inc. (ASRT), was granted equity awards.
• The awards include 24,820 Restricted Stock Units (RSUs) and 27,888 Stock Options.
• The transaction date for these grants was March 2, 2026.
• Each RSU represents a contingent right to receive one share of the registrant's common stock.
• The stock options grant the right to buy common stock at an exercise price of $11.77 per share.
• Both the RSUs and stock options were granted to the reporting person without any direct payment or consideration.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value.

Positives

• The equity grants align management's interests with shareholder value through direct equity ownership.
• This represents a standard compensation practice aimed at executive retention and motivation.

Risks

• The value of these awards is contingent on the future stock price performance of Assertio Holdings, Inc.
• Vesting of the awards is dependent on continued employment through the applicable vesting dates, posing a risk to the executive if employment ceases.

Future Outlook

The grants are intended to incentivize long-term performance and retention of the President and COO, aligning future executive efforts with shareholder value creation over the multi-year vesting period.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
• One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment through the applicable vesting date.
• The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.

Industry Context

StockSavvy.ai notes that equity grants, particularly RSUs and stock options with multi-year vesting schedules, are a standard component of executive compensation packages across the pharmaceutical and biotechnology industries. This practice aims to align executive incentives with long-term company performance and shareholder interests, a common strategy for talent retention in competitive sectors.

Comparison to Industry Standards

• The grant of RSUs and stock options to a President and COO is a common compensation structure, comparable to practices at companies like Pfizer, Johnson & Johnson, or Merck, which frequently use similar equity-based incentives for their top executives.
• The three-year graded vesting schedule (one-third per year) is a standard industry practice designed to encourage long-term commitment and performance, aligning with typical executive retention strategies seen across major pharmaceutical firms.
• The exercise price of $11.77 for the stock options is likely at-the-money on the grant date, which is typical for new grants to ensure future value is tied to stock appreciation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value through equity ownership. Minor potential for dilution from future share issuance upon vesting.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Vesting of one-third of RSUs and stock options on March 2, 2027.
• Vesting of one-third of RSUs and stock options on March 2, 2028.
• Vesting of the final one-third of RSUs and stock options on March 2, 2029.

Key Dates

Keywords

Assertio Holdings, ASRT, Paul Schwichtenberg, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Form 4